来利Larlly品牌怎么样 申请店铺

外推网助力来利Larlly品牌出海！通过在本页面挂载来利Larlly品牌的产品链接和联系邮箱，可以提高来利Larlly产品曝光！跨境电商爆单神器，目前只要100元/年哦~

来利Larlly，专业减肥药品牌，安全、健康品牌。

浙江海正药业股份有限公司，创建于1956年，为国有控股上市公司，总部位于浙江省台州市，现有员工9000多人，2000年7月“海正药业”A股在上海证券交易所上市（股票代码：600267）。海正先后获得“国家高新技术企业”、国家首批“创新型企业”、“技术创新示范企业”、“国家知识产权试点企业”、“药品出口示范基地”、全国五一劳动奖状等称号，还多次荣获“出口型企业品牌十强”、“创新型企业品牌十强”和“全国制造业500强”。2014年，荣登财富中国500强排行榜入围浙江省首批“三名”企业名单。“海正”、“HISUN”和被认定为驰名保护，并圆满完成了“抗甲流药物达菲关键中间体——环氧化物生产”国家任务，受到国务院和有关部委的表扬、省政府的单独表彰。

海正在浙江台州、杭州以及江苏如东等地区建有一体化制药基地，主营抗肿瘤、抗感染、心血管、内分泌、免疫抑制、抗抑郁、骨科等领域的原料药、制剂的研产销业务，业务遍及全球70多个国家和地区。2014年，海正药业销售收入超过100亿元。

海正建有国家认定的企业技术中心和博士后科研工作站，在北京、上海等地分别建有研发机构。每年研发投入占工业销售收入8%以上，研发人员近1200人，其中国家“千人计划”8人，省“千人计划”19人，形成了以国内科学家为主体，欧美、日本、俄罗斯等国的多名国外科学家组成的基因工程药物、微生物药物、合成药物、制剂、新药筛选等领域的科研创新人才团队。同时，围绕“生物药、化学药”两大领域开展自主品牌新药创制，与国内30所大学、研究院所产学研结合，联盟化发展，在特色原料药产业化和高端制剂产业化等形成了特色和优势。

海正积极推进民族医药创新和国际化进程，实施“五大转型”，不断推进原料制剂一体化、制剂品牌化和生物产业化，已从单纯的产品出口、贸易伙伴发展成为与国际大公司建立战略联盟，从单一的原料药出口发展为原料药与自主品牌制剂同步，从为国外大公司定制生产发展为共同创新研发。

Larlly, a professional weight-loss drug brand, is a safe and healthy brand. Zhejiang Haizheng Pharmaceutical Co., Ltd., founded in 1956, is a state-owned holding listed company with its headquarters in Taizhou City, Zhejiang Province. It has more than 9000 employees. In July 2000, "Haizheng pharmaceutical" a share was listed on the Shanghai Stock Exchange (Stock Code: 600267). Haizheng has successively won the titles of "national high and new technology enterprise", the first batch of "innovative enterprise", "technological innovation demonstration enterprise", "national intellectual property pilot enterprise", "drug export demonstration base", National May 1st Labor Medal, etc., and has also won "top 10 export-oriented enterprise brands", "top 10 innovative enterprise brands" and "top 500 national manufacturing industry" for many times. In 2014, it was listed as one of the first "three" enterprises in Zhejiang Province. "Haizheng" and "Hisun" have been recognized as well-known protection, and successfully completed the national task of "production of epoxide, a key intermediate of Tamiflu, an anti H1N1 drug", which has been praised by the State Council and relevant ministries and commissions, as well as the provincial government. Haizheng is building an integrated pharmaceutical base in Taizhou, Hangzhou, Zhejiang Province and Rudong, Jiangsu Province. It is mainly engaged in the research, production and marketing of raw materials and preparations in the fields of anti-tumor, anti infection, cardiovascular, endocrine, immunosuppression, anti depression, orthopedics, etc. its business covers more than 70 countries and regions in the world. In 2014, the sales revenue of Haizheng pharmaceutical exceeded 10 billion yuan. Haizheng has established enterprise technology centers and postdoctoral research stations recognized by the state, and R & D institutions in Beijing, Shanghai and other places. The annual R & D investment accounts for more than 8% of the industrial sales revenue, with nearly 1200 R & D personnel, including 8 in the national "thousand talents plan" and 19 in the provincial "thousand talents plan", forming a scientific research innovator in the fields of genetic engineering drugs, microbial drugs, synthetic drugs, preparations, new drug screening, etc., mainly composed of domestic scientists and many foreign scientists from Europe, America, Japan, Russia and other countries Only team. At the same time, the independent brand new drug creation is carried out around the two major fields of "biological medicine and chemical medicine", combined with the production, teaching and research of 30 universities and research institutes in China, and developed in alliance, forming features and advantages in the industrialization of characteristic APIs and high-end preparations. Haizheng has actively promoted the innovation and internationalization of national medicine, implemented the "five transformations", and continuously promoted the integration of raw materials and preparations, the branding of preparations and the bio industrialization. It has developed from a simple product export and trade partner to a strategic alliance with large international companies. It has developed from a single raw material drug export to a raw material drug and an independent brand preparation. It has developed from a single raw material drug export to a foreign company The development of manufacturing and production is joint innovation and R & D.

本文链接： https://brand.waitui.com/91230fb32.html